Klaus Sindahl
Investor Relations Contact bei HANSA BIOPHARMA AB
Profil
Klaus Sindahl is currently the Head of Investor Relations at Hansa Biopharma AB since 2019.
Prior to this, he worked at Novozymes A for 12 years from 2006 to 2018 as an Investor Relations Officer.
Aktive Positionen von Klaus Sindahl
| Unternehmen | Position | Beginn |
|---|---|---|
| HANSA BIOPHARMA AB | Investor Relations Contact | 29.04.2019 |
Ehemalige bekannte Positionen von Klaus Sindahl
| Unternehmen | Position | Ende |
|---|---|---|
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Public Communications Contact | 01.01.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HANSA BIOPHARMA AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
